| __timestamp | Iovance Biotherapeutics, Inc. | Novartis AG |
|---|---|---|
| Wednesday, January 1, 2014 | 9335772 | 14993000000 |
| Thursday, January 1, 2015 | 12390000 | 14247000000 |
| Friday, January 1, 2016 | 25602000 | 14192000000 |
| Sunday, January 1, 2017 | 21262000 | 14997000000 |
| Monday, January 1, 2018 | 28430000 | 16471000000 |
| Tuesday, January 1, 2019 | 40849000 | 14369000000 |
| Wednesday, January 1, 2020 | 60210000 | 14197000000 |
| Friday, January 1, 2021 | 83664000 | 14886000000 |
| Saturday, January 1, 2022 | 104097000 | 14253000000 |
| Sunday, January 1, 2023 | 106916000 | 12489000000 |
| Monday, January 1, 2024 | 12566000000 |
Unleashing the power of data
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, Novartis AG and Iovance Biotherapeutics, Inc. have taken different paths in optimizing these costs. From 2014 to 2023, Novartis AG consistently maintained high SG&A expenses, averaging around $14.5 billion annually. Despite a slight decrease of 16% from 2018 to 2023, their expenses remain substantial. In contrast, Iovance Biotherapeutics, Inc. has seen a dramatic increase in SG&A costs, rising by over 1,000% from 2014 to 2023, reflecting their aggressive growth strategy. This divergence highlights the strategic choices companies make in balancing cost management with growth ambitions. As the industry evolves, these decisions will continue to shape their competitive landscapes.
Selling, General, and Administrative Costs: Eli Lilly and Company vs Iovance Biotherapeutics, Inc.
Selling, General, and Administrative Costs: Novartis AG vs Zoetis Inc.
Novartis AG or Axsome Therapeutics, Inc.: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Novartis AG and Amicus Therapeutics, Inc.
Novartis AG vs MorphoSys AG: SG&A Expense Trends
Novartis AG or MannKind Corporation: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Novartis AG vs Agios Pharmaceuticals, Inc.
BioMarin Pharmaceutical Inc. and Iovance Biotherapeutics, Inc.: SG&A Spending Patterns Compared
CymaBay Therapeutics, Inc. vs Iovance Biotherapeutics, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: CRISPR Therapeutics AG vs Iovance Biotherapeutics, Inc. Trends and Insights
Breaking Down SG&A Expenses: Perrigo Company plc vs Iovance Biotherapeutics, Inc.
Who Optimizes SG&A Costs Better? Iovance Biotherapeutics, Inc. or Celldex Therapeutics, Inc.